Buy Jakafi Near Me Online – Effective Treatment for Myelofibrosis and Polycythemia Vera online
What is Jakafi?
Jakafi is a prescription medication primarily used for the treatment of myelofibrosis and polycythemia vera. This innovative treatment works by inhibiting the JAK1 and JAK2 proteins, reducing the overproduction of blood cells, which helps alleviate symptoms and improve quality of life. Patients with myelofibrosis or polycythemia vera often experience significant relief when treated with Jakafi, especially in reducing spleen size and managing blood count levels.
Jakafi is used to treat specific kinds of myelofibrosis in adults.
Jakafi is also used to treat polycythemia vera in people who have previously taken hydroxyurea and found it ineffective or intolerant.
Jakafi is used to treat acute graft versus host disease (aGVHD) in adults and children aged 12 and above who have not responded well to corticosteroids.
Jakafi works by inhibiting key enzymes in the body that regulate blood cell synthesis.
How Jakafi Works
The effectiveness of Jakafi lies in its ability to target and inhibit the Janus kinase (JAK) pathway, which plays a critical role in the development of myelofibrosis and polycythemia vera. By reducing the overactivity of this pathway, Jakafi helps control the abnormal production of blood cells. This reduces symptoms like fatigue, night sweats, and discomfort caused by an enlarged spleen. Jakafi is prescribed in specific doses according to the patient’s condition and needs.
How should I take Jakafi?
Take Jakafi exactly as directed by your doctor. Follow the recommendations on your prescription label and read any drug guidelines or instruction sheets.
Your doctor may occasionally adjust your dosage. You will need to have regular medical testing to assist your doctor establish the appropriate dose.
You can take Jakafi with or without food. Jakafi tablets can also be administered using a nasogastric (NG) feeding tube.
Read and carefully follow any instructions for use included with the medication. If you don’t understand these directions, ask your doctor or pharmacist.
Store at room temperature, free from moisture and heat. You should not stop using Jakafi abruptly. Follow your doctor’s recommendations for tapering your dosage.
Jakafi Dosage
Usual Adult Dose of Jakafi for Myeloproliferative Disorder:
Doses should be titrated depending on safety and efficacy. CBC (complete blood count) and platelet counts should be tested every 2 to 4 weeks until doses are stabilized, and then as clinically required.
Initial Dose Based on Platelet Count:
-Platelets greater than 200 x 109/L: 20 mg orally twice a day
-Platelets 100 x 10(9)/L to 200 x 109/L: 15 mg orally twice a day
-Platelets 50 x 109/L to less than 100 x 109/L: 5 mg orally twice a day
Uses: – Treats intermediate or high-risk myelofibrosis (MF), such as primary, post-polycythemia vera, and post-essential thrombocythemia MF.
Usual Adult Dose of Jakafi for Graft Versus Host Disease:
Before starting therapy, monitor complete blood counts (CBC), platelet count, ANC, and bilirubin every 2 to 4 weeks until dosages stabilize, then as clinically required.
Acute Graft Versus Host Disease (GVHD): To begin, use 5 mg orally twice a day. Titrate to 10 mg orally twice a day after 3 days if ANC and platelet counts do not decline by 50% or more compared to the first day of dosage.
Duration of therapy: Consider weaning after 6 months for those who have responded and have ceased therapeutic corticosteroid dosages; taper by 1 dose level every 8 weeks (see remarks); If signs or symptoms of GVHD persist during or after tapering, consider retreatment.
Chronic GVHD: Initial dose: 10 mg orally twice a day. – Duration of therapy: Consider tapering after 6 months for those who have responded and ceased corticosteroid therapy. Taper by 1 dose level every 8 weeks (see remarks). If signs or symptoms of GVHD persist during or after tapering, consider retreatment.
Uses: To treat steroid-refractory acute GVHD and chronic GVHD when one or two courses of systemic therapy have failed.
Usual Adult Dose of Jakafi for Polycythemia Vera:
Doses should be titrated depending on safety and efficacy, with CBC and platelet counts tested every 2 to 4 weeks until doses are stabilized, and then as clinically required.
The initial dose is 10 mg orally twice daily, which can be adjusted based on safety and efficacy.
Use: For the treatment of polycythemia vera (PV) in people who have not responded well to hydroxyurea or are intolerant of it.
Usual Pediatric Dose of Jakafi for Graft Versus Host Disease:
12 years and older:
Before starting therapy, monitor complete blood counts (CBC), platelet count, ANC, and bilirubin every 2 to 4 weeks until dosages stabilize, then as clinically required.
Acute Graft Versus Host Disease (GVHD): To begin, use 5 mg orally twice a day. Titrate to 10 mg orally twice a day after 3 days if ANC and platelet counts do not decline by 50% or more compared to the first day of dosage.
Duration of therapy: Consider weaning after 6 months for those who have responded and have ceased therapeutic corticosteroid dosages; taper by 1 dose level every 8 weeks (see remarks); If signs or symptoms of GVHD persist during or after tapering, consider retreatment.
Chronic GVHD: Initial dose: 10 mg orally twice a day. – Duration of therapy: Consider tapering after 6 months for those who have responded and ceased corticosteroid therapy. Taper by 1 dose level every 8 weeks (see remarks). If signs or symptoms of GVHD persist during or after tapering, consider retreatment.
Uses: In pediatric patients aged 12 and up, for the treatment of steroid-refractory acute GVHD and chronic GVHD after failure of one or two lines of systemic therapy.
Side Effects Of Jakafi
Common Jakafi side effects may include:
- low blood cell counts;
- swelling
- infection
- bruising
- diarrhea
- dizziness
- headache.
Some adverse effects may be comparable to those of myelofibrosis. Call your doctor immediately if you have:
- changes in the size, shape, or color of a mole or skin lesion.
- issues with speech, thinking, vision, or muscle movement (these symptoms may begin gradually and worsen rapidly);
- Symptoms include nausea, vomiting, weakness, and general malaise.
- Cold sores around your lips, skin sores or blisters, itching, tingling, skin rash, scorching sensation in your thigh or lower back;
- Pain in your arms, back, neck, jaw, or stomach.
- Signs of a stroke include sudden numbness or weakness, severe headaches, slurred speech, and vision or balance issues.
Benefits of Jakafi Treatment
Jakafi provides a unique treatment option for patients suffering from blood-related disorders like myelofibrosis and polycythemia vera. Beyond controlling symptoms, it can help improve overall health by addressing the root cause of these conditions. Patients using Jakafi report better energy levels and fewer complications related to blood clots and other risks. As with any medication, consulting with a healthcare provider regarding potential Jakafi side effects and how to best manage them is essential.
FAQ
What are JAK inhibitors and how do they work?
Janus kinase (JAK) inhibitors are a class of drugs that assist block immune system signals in the body, which can cause swelling (inflammation) and discomfort in illnesses such as rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis. They function by inhibiting enzymes that cause overactivity of the immune system.
Janus kinase (JAK) inhibitors, when used to treat rheumatoid arthritis, belong to a larger class of medications known as DMARDs (Disease-Modifying Antirheumatic medications). DMARDs can help slow down ongoing joint deterioration in rheumatoid arthritis.
JAK inhibitors are available in both oral and topical forms.
Which JAK inhibitors are approved in the U.S?
List of JAK inhibitors approved in the United States include:
- Cibinqo (abrocitinib)
- Inrebic (fedratinib)
- Jakafi (ruxolitinib)
- Litfulo (ritlecitinib)
- Ojjaara (momelotinib)
- Olumiant (baricitinib)
- Opzelura (ruxolitinib)
- Rinvoq (upadacitinib)
- Vonjo (pacritinib)
- Xeljanz (tofacitinib)
How long can you stay on Jakafi?
Jakafi is a long-term therapy. Your Healthcare Professional may allow up to 6 months to determine whether Jakafi is effective for you. If you do not experience any improvement after 6 months of treatment, your healthcare professional may advise you to discontinue taking Jakafi.
Reviews
There are no reviews yet.